You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Comparison of therapies and key clinical decisions using hepatitis C virus RNA VL

From: Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Antiviral therapy Geno-type Response guided therapy Definition of "undetectable" HCV RNA result to assess SVR (IU/mL)
   On-therapy decision? Responder time point (weeks) HCV RNA result considered "undetectable" † Treatment duration (weeks)  
PEGα/RBV 1-6 YES 4 or 12 week 4, (RVR) <50 IU/mL or week 12, (partial responder) 2 log10 drop 24, 48, or 72 < 50
PEGα/RBV +TVR 1 YES 4 and 12 TND, both RGT timepoints 24 or 48 < 25
PEGα/RBV +BOC 1 YES 8 and 16** TND, both RGT timepoints 28, 36, or 48 < 25
PEGα/RBV +SIM 1 YES* 12 < 25 IU/mL 24 or 48 < 25
PEGα/RBV +SOF 1 N/A N/A N/A 12 < 25
SOF/RBV 2, 3 N/A N/A N/A 12 or 24 < 25
  1. * Fixed duration regimen, HCV RNA VL ≥25 IU/mL is a stopping rule.
  2. ** with a 4 week lead-in (PEGα/RBV)
  3. † The test used was the COBAS® TaqMan® for Use with the High Pure System (LLOQ = 25 IU/mL, overall LOD = 20 IU/mL)
  4. HCV: Hepatitis C virus. SVR: Sustained virologic response. PEGα: Pegylated interferon alpha. RBV: ribavirin. RVR: Rapid virological response. TVR: Telaprevir. TND: Target not detected. RGT: Response guided therapy. BOC: boceprevir. SIM: Simeprevir. SOF: Sofosbuvir.